文献速递膀胱癌与上尿路尿路上皮癌

卡介苗无反应性非肌层浸润性膀胱癌的新兴免疫治疗选择

Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.
PubMed 文献 · J Urol · 2019-05-01

本文通过检索PubMed数据库、相关会议摘要及ClinicalTrials.gov,综述了卡介苗无反应性非肌层浸润性膀胱癌的现有免疫治疗选择,并讨论了靶向药物及免疫联合方案的在研情况。结论认为,继续评估免疫治疗在该人群中有明确的生物学和临床依据,早期试验数据支持进一步研究免疫检查点抑制剂等方案的获益。

要点

  • 卡介苗无反应性非肌层浸润性膀胱癌存在重要的未满足治疗需求。
  • 靶向多条免疫通路的早期免疫治疗试验数据已出现。
  • 早期数据支持进一步评估免疫检查点抑制剂等方案的获益。

核心结论

  • 继续评估卡介苗无反应性非肌层浸润性膀胱癌的免疫治疗有明确的生物学和临床依据。
  • 针对多条免疫通路的早期免疫治疗试验数据已出现,支持进一步研究免疫检查点抑制剂及其他免疫治疗方案在该人群中的获益。

研究设计与样本

  • 通过PubMed数据库检索卡介苗治疗后复发或进展的非肌层浸润性膀胱癌免疫治疗相关文献。
  • 通过检索各会议网站识别相关会议摘要。
  • 通过ClinicalTrials.gov或相关网络检索识别相关计划中及正在进行的研究。

主要发现

  • 总结了卡介苗无反应性非肌层浸润性膀胱癌目前可用的免疫治疗选择。
  • 讨论了潜在靶向药物及免疫治疗联合方案的已有及在研研究。

临床怎么用

  • 原文未据此给出推荐。
  • 作者结论认为早期免疫治疗试验数据支持进一步研究免疫检查点抑制剂及其他免疫治疗方案在该人群中的获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Due to the high rate of recurrence and progression in patients with high risk nonmuscle invasive bladder cancer, there is an important unmet need to identify new therapies. This is particularly true for patients with recurrence after optimal intravesical bacillus Calmette-Guérin therapy, who are classified as having bacillus Calmette-Guérin unresponsive disease. MATERIALS AND METHODS: The PubMed® database was searched for publications related to immunotherapy for the treatment of patients with nonmuscle invasive bladder cancer who have recurrent or progressive disease despite receiving intravesical bacillus Calmette-Guérin therapy. Relevant congress abstracts were identified through searches of individual congress websites. Relevant planned and ongoing studies were identified via ClinicalTrials.gov or associated web searches. RESULTS: We provide a summary of the currently available immunotherapy options for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer, and discuss planned and ongoing research of potential targeted agents and immunotherapy based combination regimens. CONCLUSIONS: There is a clear biological and clinical rationale for the continued evaluation of immune based therapies in the setting of bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer. Data from early phase trials with novel immunotherapies targeting multiple immune related pathways have emerged, which support additional studies to assess the benefits of immune checkpoint inhibitors and other immunotherapy based regimens for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Meng MV, Gschwend JE, Shore N, et al. Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer. J Urol. 2019. PMID: 31042108. doi:10.1097/JU.0000000000000297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。